Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
Sandro Porceddu, Florian Scotté, Matti Aapro, et al.
Frontiers in Oncology (2020) Vol. 9
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
Yungan Tao, Xu-Shan Sun, Y. Pointreau, et al.
European Journal of Cancer (2023) Vol. 183, pp. 24-37
Open Access | Times Cited: 28
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
Jordi Rubió‐Casadevall, Beatriz Cirauqui, Javier Martínez‐Trufero, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Robert I. Haddad, Kevin J. Harrington, Makoto Tahara, et al.
Cancer Treatment Reviews (2023) Vol. 119, pp. 102585-102585
Open Access | Times Cited: 10
Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) – A phase 3 randomized controlled trial
Supriya Mallick, Abhilash Dagar, Adrija Ghosh, et al.
Radiotherapy and Oncology (2024) Vol. 202, pp. 110611-110611
Closed Access | Times Cited: 3
TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance
Yoelsis García-Mayea, Cristina Mir, Laia Carballo, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3269-3269
Open Access | Times Cited: 25
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck
Robert L. Ferris, Kevin J. Harrington, Jonathan D. Schoenfeld, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102492-102492
Open Access | Times Cited: 9
Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
Mohamed Abdulla, Abdel Aziz Belal, Amr Sakr, et al.
Health Science Reports (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 4
Assessing the efficacy of palliative radiation treatment schemes for locally advanced squamous cell carcinoma of the head and neck: a meta-analysis
Gustavo Arruda Viani, André G. Gouveia, Fernando Kojo Matsuura, et al.
Reports of Practical Oncology & Radiotherapy (2023) Vol. 28, Iss. 2, pp. 137-146
Open Access | Times Cited: 4
A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation
Alexander Rühle, M. Weymann, Max Behrens, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 118, Iss. 5, pp. 1282-1293
Open Access | Times Cited: 4
PSMD1 as a prognostic marker and potential target in oropharyngeal cancer
Hae Chan Park, Hyojin Kim, J.W. Kim, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design
Robert L. Ferris, Hisham Mehanna, Jonathan D. Schoenfeld, et al.
Future Oncology (2024) Vol. 20, Iss. 12, pp. 739-748
Open Access | Times Cited: 1
Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review
Isabella Michelon, Gilca Costa Nachtigal, Maria Inez Dacoregio, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 8
Open Access | Times Cited: 1
Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma
Julianna Korns, Christina A. Wicker, Maria Lehn, et al.
Cancer Letters (2024) Vol. 606, pp. 217320-217320
Closed Access | Times Cited: 1
Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice
Agustín Falco, Thiago Bueno de Oliveira, Jon Cacicedo, et al.
Cancer Management and Research (2021) Vol. Volume 13, pp. 6689-6703
Open Access | Times Cited: 10
Radiotherapy for locally advanced head and neck cancer in elderly patients: results and prognostic factors a single cohort
Gustavo Arruda Viani, Alexandre Faustion, Aniele Freitas Bendo Danelichen, et al.
Reports of Practical Oncology & Radiotherapy (2021) Vol. 26, Iss. 1, pp. 12-19
Open Access | Times Cited: 9
Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Yulia Vugmeyster, Abhigyan Ravula, Elisabeth Rouits, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 1, pp. 52-61
Open Access | Times Cited: 3
The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis
Sebastian Zahnreich, Soumia El Guerzyfy, Justus Kaufmann, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14900-14900
Open Access | Times Cited: 3
Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial
Pierluigi Bonomo, Isacco Desideri, Monica Mangoni, et al.
Radiotherapy and Oncology (2022) Vol. 169, pp. 64-70
Closed Access | Times Cited: 4
Cisplatin combined with laser‑activated nanotherapy as an adjuvant therapy for head and neck cancer
Gee Young Lee, Jont� Myers, Sandra Pérez, et al.
International Journal of Oncology (2020)
Open Access | Times Cited: 5
Association of hearing loss and tinnitus symptoms with health‐related quality of life among long‐term oropharyngeal cancer survivors
Puja Aggarwal, Marc‐Elie Nader, Paul W. Gidley, et al.
Cancer Medicine (2022) Vol. 12, Iss. 1, pp. 569-583
Open Access | Times Cited: 3
Ways to improve the results of conservative therapy of malignant tumors of the head and neck organs. Part I. The current state of the issue (review)
О К Курпешев
Russian Journal of Oncology (2024)
Open Access
Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck – ReCisTT study
Ana Varges Gomes, Gilberto de Castro, Thiago Bueno de Oliveira, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Radioterapia e erosão - avaliação da estrutura dentária simulando diferentes cenários clínicos
Tatiana Azevedo Pêcego
(2024)
Open Access
Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast
Robert I. Haddad, Kevin J. Harrington
Targeted Oncology (2024) Vol. 19, Iss. 6, pp. 823-832
Open Access
PSMD1 as a Prognostic Marker and Potential Target in Head and Neck Cancer
Hae Chan Park, Hyojin Kim, Ji‐Yeong Kim, et al.
Research Square (Research Square) (2023)
Open Access
Page 1 - Next Page

Scroll to top